Adding irinotecan to first-line gemcitabine improves tumour response in advanced pancreatic cancer

Cancer Treatment Reviews

Volumn 31, Issue 3, 2005, Pages 236-241

  Yip, Desmond ^a   Goldstein, David ^b  

^a CANBERRA HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; EPIRUBICIN; EXATECAN; FLUOROURACIL; GEMCITABINE; IRINOTECAN; MARIMASTAT; METALLOPROTEINASE INHIBITOR; OXALIPLATIN; PEMETREXED; PROTEIN FARNESYLTRANSFERASE INHIBITOR; TIPIFARNIB; UFT; VASCULOTROPIN ANTIBODY;

ABDOMINAL PAIN; ADD ON THERAPY; ADVANCED CANCER; ANEMIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DRUG DOSE REGIMEN; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; INOPERABLE CANCER; LEUKOPENIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; METASTASIS; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PANCREAS CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SHORT SURVEY; THROMBOCYTOPENIA;

EID: 20344376393     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2005.03.003     Document Type: Note

References (17)

1. H.A. Burris 3rd M.J. Moore J. Andersen et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial [see comments] J Clin Oncol 15 1997 2403-2413
2. C.M. Rocha Lima M.R. Green R. Rotche et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate J Clin Oncol 22 2004 3776-3783
3. J.D. Berlin P. Catalano J.P. Thomas et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297 J Clin Oncol 20 2002 3270-3275
4. X. Wang Q. Ni M. Jin et al. Gemcitabine or gemcitabine plus cisplatin for in 42 patients with locally advanced or metastatic pancreatic cancer Zhonghua Zhong Liu Za Zhi 24 2002 404-407
5. V. Heinemann D. Quietzsch F. Gieseler et al. A phase III trial comparing gemcitabine plus cisplatin vs. gemcitabine alone in advanced pancreatic carcinoma Proc Am Soc Clin Oncol 21 2003 (Abstract 1003)
6. G. Colucci F. Giuliani V. Gebbia et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: A prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale Cancer 94 2002 902-910
7. C. Li Y. Chao A prospective randomized trial of gemcitabine alone or gemcitabine + cisplatin in the treatment of metastatic pancreatic cancer Proc Am Soc Clin Oncol Gastroint Canc Symp 1 2004 (Abstract 140)
8. C. Louvet R. Labianca P. Hammel et al. GemOx (gemcitabine + oxaliplatin) versus Gem (gemcitabine) in non-resectable pancreatic adenocarcinoma: Final results of the GERCOR/GISCAD Intergroup Phase III Proc Am Soc Clin Oncol 23 2004 (Abstract 4008)
9. E. O Reilly G. Abou-Alfa R. Letourneau W. Harker et al. A randomized phase III trial of DX-8951f (exatecan mesylate; DX) and gemcitabine (GEM) vs. gemcitabine alone in advanced pancreatic cancer (APC) Proc Am Soc Clin Oncol 23 2004 (Abstract 4006)
10. D. Richards H. Kindler H. Oettle R. Ramanathan et al. A randomized phase III study comparing gemcitabine + pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreas cancer Proc Am Soc Clin Oncol 23 2004 (Abstract 4007)
11. M. Reni S. Cordio A. Passardi M.G. Panucci et al. Final results of a phase III trial of gemcitibine (G) versus PEFG regimen in stage IVA or metastatic pancreatic adecnocarcinoma (PA) Proc Am Soc Clin Oncol 23 2004 (Abstract 4010)
12. S. Ohkawa Randomized controlled trial of gemcitabine in combination with UFT versus gemcitabine alone in patients with advanced pancreatic cancer Proc Am Soc Clin Oncol 22 2004 (Abstract 4131)
13. M. Buyse P. Thirion R.W. Carlson et al. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: A meta-analysis. Meta-analysis Group in Cancer Lancet 356 2000 373-378
14. J.Y. Pierga M. Robain M. Jouve et al. Response to chemotherapy is a major parameter-influencing long-term survival of metastatic breast cancer patients Ann Oncol 12 2001 231-237
15. S.R. Bramhall J. Schulz J. Nemunaitis et al. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer Br J Cancer 87 2002 161-167
16. E. Van Cutsem H. Van De Velde P. Karasek et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer J Clin Oncol 22 2004 1430-1438
17. M.J. Moore D. Goldstein J. Hamm et al. Erlotinib improves survival when added to gemcitabine in patients wtih advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clincial Trials Group Proc Am Soc Clin Oncol Gastroint Canc Symp 2 2005 (Abstract 77)